Company: NCEL
Filing Date: 2025-07-18
Form Type: F-4/A
Source: 0001213900-25-065783
Chunk: 836

Company: NewcelX Ltd.
Filing Date: 2025-07-18
Form: F-4/A
Chunk 836
---
 as other general objectives. The completion of the fundraising round and the signing of the aforementioned framework agreement for investment, along with the previous private fundraising rounds conducted by NLS in a joint effort with the Company in October 2024 and January 2025, amount to a total of approximately USD $6.7 million, as well as an additional future investment framework of USD $25 million. These represent a significant milestone in the efforts to complete the merger transaction, strengthen the equity of the Merged Company, and develop the Company’s products following the completion of the merger transaction, including the conduct of clinical trials. C. Conversion Notice re- Convertible Loan into Company Shares, in the Amount of USD $560,479 On April 14, 2025, the Company announced that, Mr. Julien Ruggieri, a significant shareholder in the Company, provided the Company a written notice of his decision to convert the remaining USD $500,000 principal balance of the convertible loan granted by him to the Company, excluding accrued interest of USD $60,479, into 279,952 ordinary shares of the Company, no par value and 349,940 non -listedwarrants, exercisable into ordinary shares (the “Ruggieri Warrants”). The conversion was carried out in accordance with the terms of the convertible loan agreement dated November 22, 2023. As a result of the accrued interest amounting at USD $60,479 (approximately NIS 222,867), on May 4, 2025, the Company announced that it will issue to Mr. Ruggieri 36,233 ordinary shares, no par value; and 9,960 non -listedRuggieri Warrants, exercisable into ordinary shares. The Ruggieri Warrants shall have an exercise price equal to 110% of the conversion price (NIS 6.77) and shall be exercisable for a period of 42 months from the date of issuance. D. Loan agreement in the amount of NIS 1 million (USD $269 thousand), on beneficial terms, between the Company and Prof. Michel Revel On April 23, 2025, the Company announced that on April 22, 2025, the Company’s audit committee and Board of Directors approved the Company’s entry into a loan agreement, on beneficial terms, with Prof. Michel Revel, the Company’s Chief Scientific Officer, who is also a significant shareholder and a director of the Company (the “Loan Agreement”, accordingly), in accordance with the